Vaccinating adults helps ease pressures on healthcare providers and delivers benefits to society more broadly. It’s time to realise that potential value in full. Vaccines are commonly associated with childhood, but their importance extends into adulthood and old age. Recent studies highlighted that adult vaccination programmes are not only beneficial for individual health but also...
Read more
The Sustainable Development Goals (SDGs) emerged from a collective ambition to create a blueprint for global action, charting the path to a better future for everyone. But, with just over five years to 2030, progress is lagging. Collective, concerted effort, supported by technological solutions, is required to achieve these goals. To unlock such innovations, the...
Read more
Ahead of negotiations on a Global Plastics “Instrument”, the innovative pharmaceutical industry put together its position. Key takeaways include: IFPMA supports an overall ambitious UN Global Plastics “Instrument” that creates globally harmonized plastic regulations. This is key to securing the scale and effect needed if we are to succeed in transitioning away from plastic where...
Read moreOn 23 April 2024, IFPMA submitted a statement to the Fourth Meeting of the Intergovernmental Negotiating Committee (INC-4) on plastics pollution in Ottawa, Canada. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) lends its full support to an ambitious UN Global Plastics “Instrument” that can help create globally harmonized rules on plastic. This is...
Read moreOn 22 April 2024, IFPMA delivered a statement at the Eighth Meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva, Switzerland.
Read moreThe evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...
Read more
Next week, Japan will host expert discussions on strengthening regulatory systems, fostering international collaboration, and advancing towards universal health coverage. This discussion is part of the Asia Partnership Conference of Pharmaceutical Associations (APAC), an industry-driven initiative focused on expediting the availability of innovative medicines across Asia. For more than 10 years, APAC has served as...
Read more
Download this OHE report, commissioned by IFPMA, to learn more about the socio-economic value of adult vaccination programems on individual lives and societies at large.
Read more
On 9 April 2024, IFPMA, Interfarma, and FIFARMA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda. The letter is available for download in English, Portuguese, and Spanish.
Read moreThe Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in April, Greece, on 3 and 4 April 2024, to discuss global health challenges and public health policies impacting biomedical innovation. 05 April 2024, Athens – The CEOs of leading biopharmaceutical companies met in Athens, Greece, to discuss collaborative solutions that can...
Read moreOn 3 April 2024 in Athens, the International Federationof Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a joint letter of intent.
Read moreVaccines remain one of the most effective public health measures we have. Learn how a greater focus on adult vaccination saves lives, boosts productivity and drives economic growth. It is estimated that four million deaths worldwide are prevented by childhood vaccination every year. Beyond the number of lives saved, the public health benefits of childhood...
Read more